Apple’s visionary founder, the late Steve Jobs once said, “the biggest innovations of the 21st century will be at the intersection of biology and technology”.
And that prediction is coming true in the drug discovery field where biology, nanotechnology and AI are uniting against previously untreatable diseases, pandemics, and human ageing.
“Out of COVID’s death and devastation and the knock-on effect upon people already weakened by cancers, heart disease and other long-term killers, it is uplifting to see how the biotech, nanomedicine and computing disciplines are responding,” said Paul Stannard, chairman of the healthcare charity World Science Aid and the World Nano Foundation – the not-for-profit that supports global commercialisation of nanotechnology.
“It’s a combination that Steve Jobs forecast with such typical vision and has already given us faster and more effective vaccine production and virus testing to push back against COVID, while starting to map out more effective health systems that major on treatment at the point of care.
“But real excitement comes from new drug discovery techniques, spearheaded by powerful computing and artificial intelligence platforms that Steve Jobs would have picked out to be disruptors just like his iMac, iPod and iPad.”
As an example, Stannard highlighted developments at a small but fast-growing Silicon Valley neighbour to Jobs’ giant Apple Inc, the AI-driven drug discovery company Verseon, which has built a proprietary technology platform to create new drugs atom by atom.
Fremont-based Verseon says the platform is far more sophisticated than the ‘AI systems’ of other drug developers, as it enables the design of the entirely new chemical structures needed to fight currently untreatable diseases.
![](https://images.squarespace-cdn.com/content/v1/57ed3edb37c58182f815c65f/ec5dd2bd-7ce3-4159-8cef-662ed3aa55dd/shutterstock_2143782715.jpg)
Biology, nanotechnology and AI combined could revolutionise modern healthcare and disease & pandemic protection.
Verseon stresses that AI is only as effective as the data available for it to learn from, as shown by issues arising from development of ‘self-driving’ vehicles; in the case of other ‘AI drug discovery systems’ this data comes only from existing drugs and past experiments.
As highlighted by current coverage in Impact Wealth Magazine, Verseon has freed itself from that conventional approach and is bringing much-needed new treatments to market for cancers, heart disease, and other killers. The company is also developing products that slow human aging and boost longevity.
Many market watchers now believe that despite the pharmaceutical industry’s $1 trillion a year patent-protected revenue, its failure-prone trial-and-error drug development process is an increasing impediment to finding badly needed disease treatments.
Verseon realized that systematic design of completely new drugs requires breakthroughs in molecular-physics modeling to determine how a new chemical structure will bind to a disease-causing protein.
And using its platform, the company has identified multiple new clinical candidates for every one of its programs – a feat unheard of in the pharmaceutical industry.
Verseon’s management team holds over 200 patents collectively and are no strangers to transformational breakthroughs.
Co-founders Adityo Prakash (CEO) and Eniko Fodor (COO) patented technologies now owned by Intel that power all video streaming today, from Amazon Prime to Zoom.
![](https://images.squarespace-cdn.com/content/v1/57ed3edb37c58182f815c65f/2a155034-2f37-4f64-b5d2-2588461a249f/Adityo+Prakash+Verseon.png)
Adityo Prakash, CO-Founder and CEO of Verseon.
The third Verseon Co-founder, Chief Science Officer (CSO) David Kita developed one of the first bioinformatics platforms that catalyzed the genomics revolution.
And Verseon’s Chief Technical Officer Sangtae Kim – a former CEO at the influential Morgridge Institute biomedical unit, and a former VP at major pharma company, Eli Lilly – is now driving enhancement of the company’s powerful AI.
“Verseon’s platform comprises significant new advances within multiple distinct branches of science,” he said.
“Any one of these advances would be enthusiastically welcomed by leading practitioners in their respective domains but collecting them together is virtually unattainable by any other organization. It is by far the most advanced ab initio drug design methodology currently in existence.”
![](https://images.squarespace-cdn.com/content/v1/57ed3edb37c58182f815c65f/43983961-f650-4dcc-b844-57cbb0a0b30d/shutterstock_1727581912.jpg)
Verseon is already trialling drugs to treat and prevent heart attacks and strokes.
![](https://images.squarespace-cdn.com/content/v1/57ed3edb37c58182f815c65f/264b3c46-0d8a-4534-8c53-bc15caca5ac3/DEANFIELD_Standing_-2-e1623756954242-600x600.jpg)
John Deanfield, University College London Professor of Cardiology.
Verseon is currently trialling drugs with remarkably low bleeding risk to treat and prevent heart attacks and strokes in over 400 million patients worldwide – uncontrolled bleeding is the biggest risk factor with current alternatives.
One of the world’s leading cardiologists John Deanfield, University College London’s Professor of Cardiology, commented:
![](https://images.squarespace-cdn.com/content/v1/57ed3edb37c58182f815c65f/d7b581ee-b2c9-443e-8e93-8e1c73154b09/KarrRobert_450.jpg)
Robert Karr, former SVP of R&D Strategy
“Verseon’s platelet-sparing anticoagulants…represent an exciting ‘precision medicine’ opportunity for the treatment of a large population of cardiovascular disease patients.”
Verseon is also developing oral drugs to treat diabetic vision loss in over 154 million patients, plus a cure for coronaviruses, and three different programs to fight cancer – one of the world’s biggest killers.
All of these are part of a fast-growing drug pipeline of 16 candidate drugs across eight programs, including cancers, heart disease, and degenerative eye diseases due to diabetes.
Pfizer’s former SVP of R&D Strategy Robert Karr said: “Verseon’s disruptive platform changes how drugs can be discovered and developed, and the company is poised to make a dramatic impact on modern medicine.”
![](https://www.nanoappsmedical.com/wp-content/uploads/2017/05/spacer.jpg)
News
The Silent Battle Within: How Your Organs Choose Between Mom and Dad’s Genes
Research reveals that selective expression of maternal or paternal X chromosomes varies by organ, driven by cellular competition. A new study published today (July 26) in Nature Genetics by the Lymphoid Development Group at the MRC [...]
Study identifies genes increasing risk of severe COVID-19
Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in [...]
Small regions of the brain can take micro-naps while the rest of the brain is awake and vice versa
Sleep and wake: They're totally distinct states of being that define the boundaries of our daily lives. For years, scientists have measured the difference between these instinctual brain processes by observing brain waves, with [...]
Redefining Consciousness: Small Regions of the Brain Can Take Micro-Naps While the Rest of the Brain Is Awake
The study broadly reveals how fast brain waves, previously overlooked, establish fundamental patterns of sleep and wakefulness. Scientists have developed a new method to analyze sleep and wake states by detecting ultra-fast neuronal activity [...]
AI Reveals Health Secrets Through Facial Temperature Mapping
Researchers have found that different facial temperatures correlate with chronic illnesses like diabetes and high blood pressure, and these can be detected using AI with thermal cameras. They highlight the potential of this technology [...]
Breakthrough in aging research: Blocking IL-11 extends lifespan and improves health in mice
In a recent study published in the journal Nature, a team of researchers used murine models and various pharmacological and genetic approaches to examine whether pro-inflammatory signaling involving interleukin (IL)-11, which activates signaling molecules such [...]
Promise for a universal influenza vaccine: Scientists validate theory using 1918 flu virus
New research led by Oregon Health & Science University reveals a promising approach to developing a universal influenza vaccine—a so-called "one and done" vaccine that confers lifetime immunity against an evolving virus. The study, [...]
New Projects Aim To Pioneer the Future of Neuroscience
One study will investigate the alterations in brain activity at the cellular level caused by psilocybin, the psychoactive substance found in “magic mushrooms.” How do neurons respond to the effects of magic mushrooms? What [...]
Decoding the Decline: Scientific Insights Into Long COVID’s Retreat
Research indicates a significant reduction in long COVID risk, largely due to vaccination and the virus’s evolution. The study analyzes data from over 441,000 veterans, showing lower rates of long COVID among vaccinated individuals compared [...]
Silicon Transformed: A Breakthrough in Laser Nanofabrication
A new method enables precise nanofabrication inside silicon using spatial light modulation and laser pulses, creating advanced nanostructures for potential use in electronics and photonics. Silicon, the cornerstone of modern electronics, photovoltaics, and photonics, [...]
Caught in the actinium: New research could help design better cancer treatments
The element actinium was first discovered at the turn of the 20th century, but even now, nearly 125 years later, researchers still don't have a good grasp on the metal's chemistry. That's because actinium [...]
Innovative Light-Controlled Drugs Could Revolutionize Neuropathic Pain Treatment
A team of researchers from the Institute for Bioengineering of Catalonia (IBEC) has developed light-activated derivatives of the anti-epileptic drug carbamazepine to treat neuropathic pain. Light can be harnessed to target drugs to specific [...]
Green Gold: Turning E-Waste Into a Treasure Trove of Rare Earth Metals
Scientists are developing a process inspired by nature that efficiently recovers europium from old fluorescent lamps. The approach could lead to the long-awaited recycling of rare earth metals. A small molecule that naturally serves [...]
Cambridge Study: AI Chatbots Have an “Empathy Gap,” and It Could Be Dangerous
A new study suggests a framework for “Child Safe AI” in response to recent incidents showing that many children perceive chatbots as quasi-human and reliable. A study has indicated that AI chatbots often exhibit [...]
Nanoparticle-based delivery system could offer treatment for diabetics with rare insulin allergy
Up to 3% of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the [...]
Nanorobot kills cancer cells in mice with hidden weapon
Researchers at Karolinska Institutet in Sweden have developed nanorobots that kill cancer cells in mice. The robot's weapon is hidden in a nanostructure and is exposed only in the tumor microenvironment, sparing healthy cells. [...]